menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company

CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 for gene editing and repair, announced today that Jennifer Doudna, PhD, and Derrick Rossi, PhD, will join Intellia as founding members and scientific advisors of the Company. Dr.
Read More

Intellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology

Five-Year Collaboration Focused on CART and Hematopoetic Stem Cell Applications across a Range of Therapeutic Areas CAMBRIDGE, Mass.—January 7, 2015—Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a
Read More

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment
Read More
RSS FEEDS
PRINT PAGE